<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45380">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02112526</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-LY-002</org_study_id>
    <nct_id>NCT02112526</nct_id>
  </id_info>
  <brief_title>ACP-196, a Btk Inhibitor, for Treatment of Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase 1b, Multicenter, Open-label Study of 2 Dosing Regimens of ACP-196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating two dosing regimens, the safety, and efficacy of a new Bruton
      tyrosine kinase (Btk) inhibitor, ACP-196, for the treatment of subjects with Relapsed or
      Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Parallel Assignment</study_design>
  <primary_outcome>
    <measure>Objective Response</measure>
    <time_frame>Up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: ACP-196 50mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: ACP-196 50mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: ACP-196 100mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: ACP-196 100mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACP-196</intervention_name>
    <arm_group_label>Cohort 1: ACP-196 50mg BID</arm_group_label>
    <arm_group_label>Cohort 2: ACP-196 100mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ 18 years of age.

          -  Pathologically confirmed de novo ABC DLBCL

          -  Relapsed or refractory disease

          -  Subjects must have ≥ 1 measurable disease sites

        Exclusion Criteria:

          -  A life-threatening illness, medical condition or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of ACP-196, or put the study outcomes at undue risk

          -  Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
             congestive heart failure, or myocardial infarction within 6 months of screening, or
             any Class 3 or 4 cardiac disease as defined by the New York Heart Association
             Functional Classification, or LVEF &lt; 40%

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel or ulcerative colitis, symptomatic
             inflammatory bowel disease, or partial or complete bowel obstruction.

          -  Lactating or pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Hamdy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Rodriguez, MHA</last_name>
    <phone>+1-650-591-4024</phone>
    <email>s.rodriguez@acerta-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>April 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Novo Activated B-cell (ABC)</keyword>
  <keyword>Novo Activated B-cell</keyword>
  <keyword>ABC DLBCL</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>B-Cell</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Immune System Diseases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
